Key Highlights
- Expansion of partnership to integrate clinical research at 158 QualDerm practices.
- More than 1.5 million annual patients will have access to innovative care options.
- Enhanced patient care with AI-driven diagnostics and research opportunities.
- Specialized dermatological care for conditions like skin cancer, psoriasis, and acne.
- Streamlined clinical trial workflow using ObjectiveHealth’s proprietary technology.
Source: Business Wire
Notable Quotes
- “We’re thrilled to be expanding our partnership with our fellow Nashvillians at QualDerm Partners to provide the option of clinical research to more than 1.5M annual patients across QualDerm’s multi-state network of highly reputable dermatology practices.” — Colleen Hoke, Co-founder and Chief Executive Officer at ObjectiveHealth
- “We’re honored to broaden our partnership with ObjectiveHealth and offer access to clinical research to even more of the patients within our affiliated practices.” — Joel Hackney, CEO at QualDerm
SoHC's Take
The expanded partnership between ObjectiveHealth and QualDerm Partners marks a significant advancement in the integration of clinical research within dermatology practices. By leveraging ObjectiveHealth’s innovative AI-driven technology and QualDerm’s extensive network of top-tier dermatologists, this collaboration is poised to enhance patient outcomes and provide broader access to cutting-edge clinical trials. This strategic move not only strengthens the clinical research infrastructure but also positions both organizations for sustainable growth and increased profitability. The focus on improving patient care through advanced diagnostics and seamless clinical trial integration sets a new standard in the dermatology field, benefiting both patients and healthcare providers alike.
